AI assistant
Denali Therapeutics Inc. — Director's Dealing 2021
Jun 8, 2021
31637_dirs_2021-06-08_ec48c62c-cef4-41f3-b725-5633173b3832.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2021-06-07
Reporting Person: Tessier-Lavigne Marc (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-06-07 | Common Stock | M | 39303 | $18.00 | Acquired | 2583673 | Direct |
| 2021-06-07 | Common Stock | M | 27830 | $18.92 | Acquired | 2611503 | Direct |
| 2021-06-07 | Common Stock | M | 27245 | $19.50 | Acquired | 2638748 | Direct |
| 2021-06-07 | Common Stock | S | 93678 | $70.345 | Disposed | 2545070 | Direct |
| 2021-06-07 | Common Stock | S | 700 | $71.063 | Disposed | 2544370 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-06-07 | Stock Option (right to buy) | $18.00 | M | 39303 | Disposed | 2027-12-07 | Common Stock (39303) | Direct |
| 2021-06-07 | Stock Option (right to buy) | $18.92 | M | 27830 | Disposed | 2028-06-13 | Common Stock (27830) | Direct |
| 2021-06-07 | Stock Option (right to buy) | $19.50 | M | 27245 | Disposed | 2029-05-30 | Common Stock (27245) | Direct |
Footnotes
F1: Includes 2,074 restricted stock units.
F2: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
F3: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $70.00 to $70.965 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F4: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $71.02 to $71.07 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F5: 25% of the shares subject to the option vested on December 7, 2018 and an additional 1/48 of the shares vest monthly thereafter.
F6: 100% of the shares subject to the option were fully vested and exercisable.